

Preliminary Programme
14th Nordic Lung cancer symposium 2020
Radisson BLU Royal Hotel Bergen, Norway May, 7th- 10th, 2020

THURSDAY MAY 7 2020

- 17.00-18.00 Exhibition
- 18.00-19.00 SATELLITE SYMPOSIUM (Topic: Targeted therapy)
Chairman: TBC
Sponsored by: TBC
- RECEPTION

FRIDAY MAY 8 2020

- 08.30-09.00 WELCOME, PROGRAMME OVERVIEW
Marianne Aanerud, Odd Terje Brustugun (Norway, NO),
Eeva-Maija Nieminen (SF), Jens Benn Sørensen (Denmark, DK),
Signe Friesland (S)
- 09.00-10.20 LUNG CANCER DIAGNOSIS AND SCREENING
Chairman: Torben Riis Rasmussen (DK)
Presentations 15 minutes followed by 5 minutes discussion
- 09.00 LUNG CANCER SCREENING: Who should be screened? Implementation issues in Nordic countries?
Haseem Ashraf (DK)
- 09.20 BLOOD BASED SCREENING
Åslaug Helland (NO)
- 09.40 SCREENING EXPERIENCE FROM SWEDEN
Hirsh Koyi (S)
- 10.00 RESULTS FROM THE NORWEGIAN LUNG CANCER REGISTRY
Lars Fjellbirkeland (NO)
- 10.20-10.50 COFFEE BRAKE, EXHIBITION, AND POSTERS
- 10.50-12.15 EARLY STAGE LUNG CANCER
Chairman: Antti Jekunen (SF)
Presentations 15 minutes followed by 5 minutes discussion
- 10.50 ARE ROBOTS HERE TO STAY?
Rune Eggum (NO)
- 11.30 FOLLOW-UP OF SMALL NODULES – BEST PRACTICE?
Aija Knuutila (FI)
- 11.50 IO IN RESECTABLE AND IN LOCALLY ADVANCED NSCLC, BOTH SINGLE AGENTS AND COMBOS?
Bjørn Henning Grønberg (NO)
- 12.15-13.15 SATELLITE SYMPOSIUM (TOPIC: Immuno-oncology)
Chairman: TBC
Sponsored by: TBC
- 13.15-14.15 LUNCH AND EXHIBITION, POSTERS

- 14.15-15.45 COFFEE BREAK, EXHIBITION, POSTERS
- 15.45-16.30 **LOCALLY ADVANCED NSCLC**
Chairman: Signe Friesland (S)
Presentations 15 minutes followed by 5 minutes discussion
- 15.45 SBRT IN OLOGIMETASTATIC DISEASE – ANY LIMITS?
Luigi de Petris (SE)
- 16.05 IMMUNORADIOTHERAPY – A DANGEROUS ENDEAVOR?
Andreas Hallquist (DK)

SATURDAY MAY 9 2020

- 8.30-10.15 **ONCOGEN DRIVEN NSCLC**
Chairman: Odd Terje Brustugun (NO)
Presentations 15 minutes followed by 5 minutes discussion
- 08.30 SMALLER AND SMALLER TREATMENT GROUPS - HOW TO IMPLEMENT DIAGNOSIS AND TREATMENT?
Simon Ekman (S)
- 08.50 CLINICAL ALK EXPERIENCE
Marianne Aanerud (NO)
- 09.10 INTRODUCTION OF “EXPENSIVE DRUGS” – HOW TO LEARN FROM EACH OTHER
Anders Vikström (S)
- 09.30 EGFR INTRINSIC AND ACQUIRED RESISTANCE MECHANISMS
Eric Santoni-Ruggiu (DK)
- 09.50 TIME FOR ROUTINE USE OF NGS IN THE INITIAL DIAGNOSTIC PROCESS IN NSCLC?
Jussi Koivonen (FI)
- 10.15-10.45 COFFEE, EXHIBITION, AND POSTERS
- 10.45-11.45 **SATELLITE SYMPOSIUM (topic: novel diagnostics)**
Chairman: TBC
Sponsored by: TBC
- 11.45-12.45 LUNCH AND EXHIBITION, POSTERS
- 12.45-13.45 ORAL PRESENTATION OF SELECTED ABSTRACTS
- 13.45-15.15 **IMMUNO-ONCOLOGY**
Chairman: Jens Benn Sørensen (DK)
Presentations 15 minutes followed by 5 minutes discussion
- 13.15 PD-L1, TUMOR MUTATIONAL BURDEN; AND OTHER MARKERS FOR IMMUNOTHERAPY
Henrik Hager (DK)
- 13.35 OPTIMAL COMBINATIONS OF IO
Jon Lykkegaard Andersen (DK)
- 13.55 THE FINNISH EXPERIENCE
Jarkko Ahvonen (FI)
- 14.15 LONG-TERM EXPERIENCE OF IO IN CLINICAL PRACTICE
Øystein Fløtten (NO)
- 15.15-15.45 COFFEE BREAK
- 15.45-16.45 **BREAKOUT SESSIONS**
- A: LUNG CANCER SCREENING - CLINICAL EXPERIENCES IN NORDIC COUNTRIES**
Chairman: Hirsh Koyi (S)

B: IMPLEMENTATION OF EXPENSIVE DRUGS – LEARNING FROM EACH OTHER
Chairman Jussi Koivunen (SF)

C: CLINICAL AND REGISTRY RESEARCH – POSSIBILITIES FOR NORDIC COLLABORATION
Chairmen Antti Jekunen (SF) and Bjørn Henning Grønberg (NO)

D: PALLIATIVE CARE
Chairman Anne Kari Knudsen (NO)

DINNER

SUNDAY MAY 10 2020

- 09.00-9.45 SPECIAL TOPICS IN LUNG CANCER
Chairman Eeva-Maija Nieminen (SF)
- 09.00 PATIENT REPORTED OUTCOME (PRO) IN RELATION TO LUNG CANCER
Chairman: Rasmus Blechingverg Friis (DK)
- 09.20 PALLIATION IN THE ERA OF SOM MANY TREATMENT POSSIBILITIES – HOW TO SAY “NOT MORE”
Eeva-Maja Nieminen (FI)
- 09.45-10.10 COFFEE, EXHIBITION, AND POSTERS
- 10.30-12.20 SCLC AND MESOTHELIOMA
Chairman: Jens Benn Sørensen (DK)
Five minutes discussion after each presentation
- 10.30 SCLC – IMMUNOTHERAPY AND OTHER APPROACHES
Tine Schytte (DK)
- 10.50 SURGERY in SCLC – TOO OFTEN OR TOO SELDOM?
Bengt Bergman (S)
- 11.10 SHOULD WE CONTINUE TO PROVIDE PCI IN SCLC?
Jan Nyman (S)
- 11.35 WHERE ARE WE MOVING IN MALIGNANT MESOTHELIOMA
Ronny Öhman (S)
- 12.00 UPDATES ON SURGERY IN MESOTHELIOMA
Jesper Ravn (DK)
- 12.30 LUNCH AND ADJOURN